To sling or not to sling? Impact of intraoperative sling procedures during radical prostatectomy on postoperative continence outcomes: A systematic review and meta-analysis

Eunice Lim1,2,3,4 | Scott Leslie1,3 | Ruban Thanigasalam1,2,3 | Daniel Steffens3,4

Abstract

Purpose: This systematic review and meta-analysis investigates the efficacy of intraoperative sling procedures in reducing postprostatectomy urinary incontinence compared to having no slings.

Methods: A comprehensive search of PubMed, Medline, Embase, and the Cochrane library from inception to November 2020 was performed. Risk of bias was assessed using the Cochrane Risk of Bias tool for randomized studies and Newcastle-Ottawa Scale for nonrandomized studies. The GRADE approach was used for critical appraisal of evidences and meta-analyses were conducted using random-effects models.

Results: Ten studies were included (n = 1,447). Quality of evidence ranged from moderate to very low. Sling procedure was generally favorable for short-term continence outcomes, although discrepancies exist due to variability in continence definition. Sling procedure resulted in reduced urinary pad weight at 1 month postoperatively (MD: 21.55; 95%CI: 12.58 to 30.52). Patient-reported questionnaires were also favorable for the sling group for up to 3 months (IPSS; (MD: 1.44; 95%CI: 0.14 to 2.74), ICIQ-SF; (MD: 2.25; 95%CI: 1.26 to 3.24), EPIC-U; (MD: 5.30; 95%CI: 1.12 to 9.39)) postoperatively. Sling procedure improved the number of continent patients at 1 month with continence definition of zero pad use/day (RR:1.41; 95%CI: 1.10 to 1.83) but not with the definition of ≤ 1 pad/day. Similarly, it reduced the time to continence with the ≤ 1 pad/day definition (MD: 0.5; 95%CI: 0.1 to 0.9) but not with the zero pad/day definition.

Conclusion: The current literature suggests that intraoperative sling procedures during radical prostatectomy may promote early return of continence compared to having no sling, however, there are no long-term differences.

Keywords
incontinence, intraoperative slings, prostatectomy
1 | INTRODUCTION

Prostate cancer is the second most common malignancy in men worldwide, with 1.3 million new cases in 2018.1 Radical prostatectomy is an effective and commonly performed treatment option for localized prostate cancer.2 However, urinary incontinence remains a major adverse event following radical prostatectomy, with 12 months postoperative urinary incontinence rate ranging from 4% to 31%.3 Urinary incontinence can have a severe impact on the patient's quality of life, and thus, remains a deterrent for many patients when deciding treatment for their prostate cancer.3

Multiple etiologies have been proposed for the development of postoperative incontinence with the major factor attributed to intraoperative damage of the urethral sphincter with accompanying intrinsic sphincter deficiency.5 Other possible causes include detrusor over and under-activity, bladder outlet obstruction due to anastomotic strictures and damage to pelvic nerves that potentially supply the sphincter mechanism. As such, several intraoperative techniques aiming to reduce postoperative urinary incontinence have been described, including surgical techniques to preserve anatomical structures (ie, bladder neck, neurovascular bundle, or puboprostatic ligaments) and different surgical approaches including anterior and posterior reconstruction and the Retzius-sparing technique.5,6 However, the role of these intraoperative techniques in reducing incontinence remains unclear; with many of these techniques not externally validated in a multicenter setting.7-9

Recent studies suggest that the use of intraoperative suburethral sling techniques during prostatectomy may reduce the incidence of postoperative urinary incontinence.10 Sling suspension technique involves the placement of a sling to support the proximal urethra and bladder neck to provide compressive force on the urethra, increase the functional length of the urethra and maintain adequate urethral closure.5 Sling techniques are commonly used in the setting of postoperative urinary incontinence when noninvasive therapies such as pelvic floor muscle training and pharmacologic treatments fail.11 Performing a sling procedure intra-operatively at the time of prostatectomy may prevent the development of urinary complications, improving postoperative quality of life and reducing overall cost by minimizing the likelihood of patients having to undergo secondary surgery for incontinence following radical prostatectomy.

Different surgical techniques and sling materials have been explored with varying results. Therefore, the purpose of this study is to conduct a systematic review and meta-analysis to evaluate the effectiveness of intraoperative slings compared with no sling procedure in reducing postoperative urinary incontinence and complication rates in patients undergoing radical prostatectomy.

2 | MATERIALS AND METHODS

This systematic review and meta-analysis was registered with PROSPERO (https://www.crd.york.ac.uk/PROSPERO/, CRD42017078878) prior to commencement of the review. The protocol followed the methods recommended by the Cochrane Handbook for Systematic Reviews of Interventions12 and was written in accordance with PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols) statement.13

2.1 | Search strategy

A sensitive search was performed from inception to November 2020 in MEDLINE via OVID, EMBASE via OVID, PubMed (www.ncbi.nlm.nih.gov/pubmed) and Cochrane Central Register Clinical Trials (CENTRAL) via the Cochrane Library, using key words related to “prostate cancer,” “prostatectomy,” “sling,” and “urinary incontinence” (Table S1). No language restrictions were applied. In addition, reference lists of all included studies were screened.

One reviewer inspected the titles and abstracts of all identified studies to generate a list of potentially eligible studies (EL). Full-text articles were reviewed by two review authors for eligibility (EL and DS). Consensus between the two reviewers was used to resolve any disagreement.

2.2 | Inclusion and exclusion criteria

The studies included in this review reported data on localized prostate cancer patients who underwent radical prostatectomy at any age. Study types included randomized controlled trials and nonrandomized comparative studies.

Exclusion criteria includes animal studies, conference abstracts or poster publications, and descriptive commentaries.

2.3 | Outcome measures

The main outcomes of interest were urinary incontinence and other adverse events or complications. Length of hospital stay, length of operation, quality of life, and cost were also investigated. Postoperative outcome data were extracted at 4 time points: 1, 3, 6, and 12 months.

2.4 | Data extraction

Two review authors used a pre-piloted data extraction sheet to extract data from the included studies (EL and DS). Consensus between the two reviewers was used to resolve any disagreement. An attempt was made to contact authors from studies where data were unclear or not available in the published manuscript.

For each included study the following data were extracted: sample characteristics (country, study design, surgical procedure, sling position, sling material, age, body mass index, prostate specific antigen (PSA), name of sling procedure used, and all outcome measures from all time points.
2.5 | Risk of bias assessment and strength of the evidence

Cochrane Collaboration’s tool was used to assess the methodological quality of randomized controlled trials.12 Each study was assessed as having high, low, or unclear risk of bias by two reviewers (EL and DS). Methodological quality of comparative studies was assessed via the Newcastle-Ottawa Scale (NOS), which was endorsed by the Cochrane handbook for quality appraisal of observational studies.14,15 Each study was given a score between zero and nine, by considering three factors that consist of nine items in total: (1) Selection of study groups, (2) Comparability and (3) Outcome of interest.14 Our review considered a study with a score of ≥ 7 as having high quality and low risk of bias, as there are no established standardized criteria for the interpretation of the NOS scores currently. Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess strength of evidence from high to very-low-quality for each outcomes.16

2.6 | Statistical analysis

For dichotomous outcomes, we extracted the number of patients in each group who experienced the outcome of interest and the number of patients assessed at endpoint in each treatment arm at the end of the prespecified follow-up, in order to estimate a relative risk and its 95% confidence interval. For continuous outcomes, we extracted the final value and standard deviation of the outcome of interest and the number of patients assessed at the endpoint in each treatment arm at the end of follow-up. Where appropriate, we calculated the mean difference and 95% confidence interval.

Outcome measures from individual trials were combined through a meta-analysis where possible using a random-effects model, via the Comprehensive Meta-Analysis software.17 When a meta-analysis was not possible, results were described qualitatively.

Included studies were grouped by outcome measures (eg, continence defined as zero pad/day), followed by time frame (1, 3, 6, and 12 months) to provide a homogenous subset for meta-analysis. Time points (1, 3, 6, and 12 months) were selected based on the available results. Studies included in the meta-analysis were ordered chronologically.

3 | RESULTS

3.1 | Literature search

The search identified 179 citations after the removal of duplicates. Following the elimination of irrelevant references, 31 full-text articles were screened for eligibility. About 21 articles were excluded due to
| Author, year  | Country where study was performed | Study design       | Procedure   | Sling position | Sling material                        | PSA (SD)     | Age, years (SD) | BMI (SD) | Intervention (Baseline N/Follow-up N) | Control (Baseline N/Follow-up N) |
|--------------|-----------------------------------|--------------------|-------------|----------------|--------------------------------------|--------------|-----------------|----------|--------------------------------------|--------------------------------|
| Altinova, 2009 | Turkey                            | RCT                | RRP         | Bladder neck   | Rectus fascia/1-prolene               | 12.96 (10.39) | 63.47 (7.23)    | NR       | Anterior Rectus Fascial Sling (40/40) | No sling (46/46)                |
| Bahler, 2016  | US                                | RCT                | RARP        | Bladder neck   | Small intestinal submucosa            | 6.21 (3.47)  | 60.7 (6.6)      | 29.7 (5.16) | Cook Biodesign Surgisis urethral sling (74/60) | No Sling (73/55)                |
| Westney, 2006 | US                                | Retrospective Cohort Study | RRP         | Bladder neck   | Rectus fascia/0-prolene               | NR           | NR              | NR       | Suburethral sling (49/46)           | No Sling (122/89)               |
| Nguyen, 2017  | US                                | RCT                | RARP        | Bladder neck   | Vas deferens/vicryl                   | 6.75 (1.44)  | 63.35 (6.53)    | NR       | Retropubic urethral sling (93/82)    | No sling (99/86)                |
| Cestari, 2015 | Italy                             | RCT                | RARP        | Bladder neck   | Denonvillers’ fascia/2-0 viscryl     | 8.63 (3.83)  | 63 (9.0)        | 25.9     | Retropubic suburethral autologous sling (30/30) | No Sling (30/30)                |
| Kojima, 2014  | Japan                             | RCT                | RARP        | Bladder neck   | Vas deferens/3-0 v-loc                | 7.35 (1.09)  | 65.7 (2.27)     | 23.4     | Bladder neck sling (27/27)           | No Sling (30/30)                |
| Jorion, 1997  | Belgium                           | Retrospective Cohort Study | RRP         | Bladder neck   | Rectus fascia                         | NR           | 64 (5.92)       | NR       | Rectus Fascial Sling (30/30)         | No Sling (30/30)                |
| Punnen, 2014  | US                                | Retrospective Cohort Study | RARP        | Bladder neck   | Median umbilical ligament or vas deferens/3-0 v-loc | 5.93 (6.43)  | NR              | NR       | Retropubic urethral sling (156/153)  | No Sling (81/78)                |
| Jones, 2005   | US                                | Retrospective Cohort Study | RRP         | Bladder neck   | Porcine small intestine submucosa/polylactin mesh | NR           | 60.15 (7.28)    | NR       | Strategis sling or polyglactin mesh (15/15) | No Sling (15/15)                |
| Zanoni, 2020  | Italy                             | Prospective cohort study | RARP        | Bladder neck   | Retrotroglonal muscular layer         | 6.05 (3.52)  | 60.58 (7.71)    | 24.02 (4.15) | TZ sling (157/157)                   | No Sling (250/250)               |

Note: BMI, body mass index; NR, not reported; PSA, prostate specific antigen; RARP, robotic assisted radical prostatectomy; RCT, randomized controlled trial; RRP, retropubic radical prostatectomy; SD, standard deviation.
the following reasons: conference abstracts \((n = 2)\); ineligible study design \((n = 3)\); and no outcome of interest \((n = 16)\). Therefore, 10 studies \(10,18–26\) were included in this systematic review \((n = 1,447)\) (Figure 1).

### 3.2 Study characteristics

Included trials consisted of five RCTs \(18–22\) and five retrospective cohort studies \(10,23–26\). All slings were positioned on the bladder neck, and sling material used included rectus fascia \((n = 3)\), small intestinal submucosa \((n = 2)\), vas deferens \((n = 3)\), Denonvilliers’ fascia \((n = 1)\), median umbilical ligament \((n = 1)\), and retrotrigonal muscular layer \((n = 1)\). All slings identified and included in the study were nonsynthetic slings (Table 1).

The mean age reported in the studies was 62.06. All studies found were in English. The characteristics of included studies including type of surgical approach are presented in Table 1.

### 3.3 Risk of bias assessment

The risk of bias assessments of the included studies are presented in Tables 2 and 3.

### 3.4 Cochrane collaboration’s tool for randomized controlled trials

Three studies had at least one domain with high risk of bias (Table 2). The most common methodological flaw was found in the “blinding of participants and personnel” and “other source of bias,” which included selection bias and recall bias. Least methodological flaws were found in the domain of “selective reporting.”

### 3.5 Newcastle-Ottawa scale for comparative studies

One study was assessed to have low risk of bias and four studies had high risk of bias (Table 3). Low score was observed in the domain of comparability in all studies. Risk of bias was lower in the domain of selection and outcome.

### 3.6 Continence outcomes

#### 3.6.1 Continence defined by number of pads \(10,18–20,22–24,26\)

Our meta-analysis demonstrated a very-low to moderate-quality evidence that with continence defined as using zero pad/day, number of continent patients is significantly increased in the sling group at 1 month \((RR:1.41; 95\%CI: 1.10 \text{ to } 1.83)\), but not at 3 months \((RR:1.29; 95\%CI: 0.98 \text{ to } 1.69)\), 6 months \((RR:1.10; 95\%CI: 1.00 \text{ to } 1.21)\), or 12 months \((RR:1.12; 95\%CI: 1.00 \text{ to } 1.25)\) postoperatively \((n = 746)\) (Figure 2).\(^{10,18–20,22–24}\) However, with continence definition of \(\leq 1\) pad/day, there was a low to moderate-quality evidence that sling procedures did not reduce the risk of incontinence at 1 month \((RR:1.12; 95\%CI: 1.00 \text{ to } 1.24)\), 3 months \((RR:1.07; 95\%CI: 0.95 \text{ to } 1.07)\), 6 months \((RR:1.01; 95\%CI: 0.95 \text{ to } 1.07)\), and 12 months \((RR:1.02; 95\%CI: 0.93 \text{ to } 1.13)\) postoperatively \((n = 794)\) (Figure 2).\(^{10,18–20,22–24}\)

Sling procedure did not reduce the time taken to achieve continence with zero pad/day definition \(20,25\) \((n = 296)\) (MD: 1.29; 95\%CI: −0.54 to 3.13) (Figure 3). Study by Bahler et al. was not included in this meta-analysis as the study did not report confidence interval for the data, however, the study coincides with our finding \(18\) \((n = 104)\) (MD: −0.4; \(p = 0.61; 95\%\) CI: not reported). However, with \(\leq 1\) pad/day definition, sling group achieved continence 0.5 week earlier than the no-sling group \((MD: 0.5; 95\%CI: 0.1 \text{ to } 0.9)\).\(^{25}\)

Furthermore, sling procedure did not reduce the number of pads required per day \((n = 60)\) at 5 days \((MD: −0.4; 95\%CI: −0.9 \text{ to } 0.5)\) and 10 days postoperatively \((MD: −0.5; 95\%CI: −1.2 \text{ to } 0.2)\). Yet, there was a low-quality evidence demonstrating reduced pad use in the sling group at 1 month \((MD: −0.7; 95\%CI: −1.2 \text{ to } −0.2)\).\(^{19}\) There was a low-quality evidence that sling procedure does not result in more patients achieving immediate continence after catheter removal \((n = 59)\) \((RR: 1.31; 95\%CI: 0.69 \text{ to } 2.51)\).\(^{20}\)

---

**TABLE 2** Risk of bias assessment of randomized trials via Cochrane Collaboration’s tool for Randomized Controlled Trials

| Author, year | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other source of bias |
|--------------|----------------------------|------------------------|--------------------------------------|------------------------------|-----------------------|---------------------|---------------------|
| Altinova, 2009 | Unclear | Unclear | Unclear | Unclear | Low risk | Low risk | Low risk |
| Bahler, 2016 | Low risk | Low risk | High risk | Unclear | High risk | Low risk | High risk |
| Nguyen 2017 | Unclear | Unclear | High risk | Low risk | Low risk | Low risk | High risk |
| Cestari 2015 | Low risk | Low risk | Unclear | Low risk | Low risk | Low risk | Low risk |
| Kojima 2014 | Unclear | Unclear | High risk | Low risk | Low risk | Low risk | High risk |

Notes: Low risk of bias, Low risk of bias present in the study; High risk of bias, High risk of bias present in the study; Unclear, Insufficient information to permit judgment of “Low risk” or “High risk.”
Continence defined by pad weight via 1-hour pad test

There is a very-low-quality evidence that sling procedure reduces the mean pad weight gain at 1 month (MD: 21.55; 95% CI: 12.58 to 30.52) but not at 3 months (MD: 0.00; 95% CI: −4.12 to 4.12) and 6 months (MD: 0.41; 95% CI: −0.79 to 1.91) postoperatively (n = 57).

Patient reported outcomes measures

A significant difference in International Consultation on Incontinence Questionnaire short-form (ICIQ-SF) favoring the sling group was found at 3 months (MD: 2.25; 95% CI: 1.26 to 3.24) but not at 1 month (MD: 2.77; 95% CI: −1.54 to 7.08) (Figure 4) or 6 months (MD: 0.5; 95% CI: −0.63 to 1.63). For Expanded Prostate Cancer Index Composite (EPIC-U) results, a significant difference favoring sling procedures is seen at 1 month (MD: 15.35; 95% CI: 11.37 to 19.33), 3 months (MD: 5.30; 95% CI: 1.21 to 9.39) but not at 6 months (MD: 4; 95% CI: −0.04 to 8.04) postoperatively. In addition, a significant difference in International Prostate Symptom Score (IPSS) favoring the sling group was found at 1 month (MD: 4.75; 95% CI: 3.67 to 5.83) and 3 months (MD: 1.44; 95% CI: 0.14 to 2.74) but found to favor the no-sling group at 6 months (MD: −0.94; 95% CI: −1.77 to −0.11).

Adverse events and complications

There is a very-low-quality evidence that sling does not reduce the incidence of bladder neck contracture (n = 177) (RR: 0.34; 95% CI: 0.04 to 3.12) and moderate-quality evidence of no effect on pelvic abscess formation (n = 318) (RR: 2.63; 95% CI: 0.50 to 13.70). However, there is a low-quality evidence of reduced incidence of urethral stricture (n = 348) (RR: 2.35; 95% CI: 1.33 to 4.13) and very-low-quality evidence of reduced incidence of urinary retention (n = 297) (RR: 2.09; 95% CI: 1.26 to 3.49) in the sling group (Figure 5).

Length of hospital stay, length of operation, quality of life and cost

Cestari et al. reported that sling procedure does not reduce hospital length of stay (MD: 0.0; P-value not reported; 95% CI not reported) (n = 60). Sling procedure, however, resulted in increase in the length of operation (MD: −6.13, 95% CI: −9.18 to −3.07) (Figure 6). Our search did not find any study investigating differences in quality-of-life outcomes and cost.

Discussion

Our systematic review demonstrates that there is a low-moderate certainty evidence that intraoperative sling procedures are generally
### FIGURE 2
Forrest plot of continence outcomes when continence is defined as using 0 pad versus ≥ 1 pad or as using ≤ 1 pad versus > 1 pad

| Author, year | Sling group | No Sling group | Relative Risk (95% CI) | RR (95% CI) | Weight (%) |
|--------------|-------------|----------------|------------------------|-------------|------------|
| Continen: 1 month (0 pad versus ≥1 pad) | Continence / Total | Continence / Total | | | |
| Jorion, 1997 | 16 / 30 | 10 / 30 | 1.80 (1.00 to 3.23) | 19 | |
| Jones, 2005 | 10 / 15 | 6 / 15 | 1.67 (0.81 to 3.41) | 13 | |
| Cestari, 2015 | 23 / 30 | 14 / 30 | 1.94 (1.07 to 3.53) | 35 | |
| Bahler, 2016 | 13 / 67 | 13 / 68 | 1.01 (0.51 to 2.03) | 14 | |
| Nguyen, 2017 | 17 / 93 | 19 / 99 | 0.95 (0.53 to 1.72) | 19 | |
| Pooled effect (I²=0%) |
| Jorion, 1997 | 28 / 30 | 21 / 30 | 1.41 (1.10 to 1.83) | 32 | |
| Jones, 2005 | 14 / 15 | 7 / 15 | 2.00 (1.15 to 3.49) | 15 | |
| Cestari, 2015 | 25 / 30 | 18 / 30 | 1.39 (1.00 to 1.94) | 27 | |
| Nguyen, 2017 | 36 / 91 | 41 / 92 | 0.89 (0.63 to 1.25) | 26 | |
| Pooled effect (I²=15.17%) |
| Jorion, 1997 | 30 / 30 | 27 / 30 | 1.11 (0.97 to 1.27) | 50 | |
| Jones, 2005 | 14 / 15 | 12 / 15 | 1.17 (0.88 to 1.55) | 11 | |
| Westney, 2006 | 19 / 49 | 52 / 118 | 0.88 (0.59 to 1.32) | 5 | |
| Cestari, 2015 | 28 / 30 | 22 / 30 | 1.27 (1.01 to 1.61) | 16 | |
| Nguyen, 2017 | 53 / 82 | 57 / 86 | 0.98 (0.78 to 1.22) | 18 | |
| Pooled effect (I²=0%) |
| Jorion, 1997 | 30 / 30 | 28 / 30 | 1.10 (1.00 to 1.21) | 21 | |
| Jones, 2005 | 14 / 15 | 14 / 15 | 1.07 (0.96 to 1.20) | 35 | |
| Westney, 2006 | 19 / 49 | 56 / 89 | 0.92 (0.69 to 1.22) | 11 | |
| Cestari, 2015 | 28 / 30 | 22 / 30 | 1.16 (1.09 to 1.95) | 11 | |
| Nguyen, 2017 | 53 / 82 | 57 / 86 | 1.21 (1.00 to 1.46) | 21 | |
| Pooled effect (I²=15.82%) |
| Jorion, 1997 | 11 / 30 | 10 / 30 | 1.10 (0.55 to 2.19) | 2 | |
| Bahler, 2011 | 37 / 67 | 32 / 68 | 1.17 (0.64 to 1.84) | 11 | |
| Nguyen, 2017 | 42 / 93 | 49 / 99 | 1.15 (1.01 to 1.30) | 74 | |
| Zanoni, 2020 | 119 / 157 | 165 / 250 | 1.12 (1.00 to 1.24) | 40 | |
| Pooled effect (I²=0%) |
| Jorion, 1997 | 29 / 30 | 20 / 30 | 1.45 (1.12 to 1.88) | 15 | |
| Bahler, 2011 | 49 / 65 | 48 / 65 | 1.02 (0.84 to 1.25) | 20 | |
| Nguyen, 2017 | 69 / 91 | 69 / 92 | 1.01 (0.86 to 1.19) | 25 | |
| Zanoni, 2020 | 138 / 157 | 215 / 250 | 1.02 (0.95 to 1.10) | 40 | |
| Pooled effect (I²=28.32%) |
| Jorion, 1997 | 30 / 30 | 29 / 30 | 0.93 (0.97 to 1.07) | 17 | |
| Westney, 2006 | 29 / 49 | 83 / 118 | 0.84 (0.65 to 1.09) | 9 | |
| Bahler, 2016 | 50 / 59 | 51 / 59 | 0.98 (0.85 to 1.14) | 18 | |
| Nguyen, 2017 | 72 / 82 | 74 / 86 | 1.02 (0.91 to 1.15) | 29 | |
| Pooled effect (I²=0%) |
| Jorion, 1997 | 30 / 30 | 29 / 30 | 1.03 (0.94 to 1.13) | 47 | |
| Westney, 2006 | 29 / 49 | 83 / 118 | 0.88 (0.72 to 1.07) | 19 | |
| Bahler, 2016 | 52 / 55 | 52 / 60 | 1.09 (0.97 to 1.23) | 36 | |
| Pooled effect (I²=18.21%) |

### FIGURE 3
Forrest plot of time taken to achieve continence (months)
favorable for short-term improvement but have no difference in long-term continence outcomes compared to having no sling procedures (Table 4). Early return of continence in the sling group is seen in patient-reported questionnaires for up to 3 months (IPSS, ICIQ-SF, and EPIC-U) postoperatively. Furthermore, significant improvement is seen in the sling group at 1 month for pad weight test, number of pads used per day, and number of continent patients with zero pad/day definition, although no difference is discerned at longer term.

However, sling procedure does not increase the number of continent patients at any time point with ≤1 pad/day definition. As such, it is evident that variability in results is introduced by the difference in continence definition and methods. Similarly, sling procedure
| Outcome—Time point (definition) [references] | Summary of findings | Quality of evidence assessment (GRADE) |
|-----------------------------------------------|----------------------|---------------------------------------|
| **Continence**                               |                      |                                       |
| **Continence—1 month (0 pad versus ≥ 1 pad) [Jorion, 1997; Jones, 2005; Cestari, 2015; Bahler, 2016; Nguyen, 2017]** | Number of participants (studies): 477 (3 RCTs/2 comparative studies) | Effect size (95%CI): RR: 1.41 (1.10 to 1.83) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—3 months (0 pad versus ≥ 1 pad) [Jorion, 1997; Jones, 2005; Cestari, 2015; Nguyen, 2017]** | Number of participants (studies): 333 (2 RCTs/2 comparative studies) | Effect size (95%CI): RR: 1.29 (0.98 to 1.69) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—6 months (0 pad versus ≥ 1 pad) [Jorion, 1997; Jones, 2005; Westney, 2006; Cestari, 2015; Nguyen, 2017]** | Number of participants (studies): 485 (2 RCTs/3 comparative studies) | Effect size (95%CI): RR: 1.10 (1.00 to 1.21) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—12 months (0 pad versus ≥ 1 pad) [Jorion, 1997; Jones, 2005; Westney, 2006; Altinova, 2009; Cestari, 2015]** | Number of participants (studies): 371 (2 RCTs/3 comparative studies) | Effect size (95%CI): RR: 1.12 (1.00 to 1.25) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—1 month (≤ 1 pad versus > 1 pad) [Jorion, 1997; Bahler, 2011; Nguyen, 2017; Zanoni, 2020]** | Number of participants (studies): 794 (2 RCTs/2 comparative study) | Effect size (95%CI): RR: 1.12 (1.00 to 1.24) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—3 months (≤ 1 pad versus > 1 pad) [Jorion, 1997; Bahler, 2011; Nguyen, 2017; Zanoni, 2020]** | Number of participants (studies): 780 (2 RCTs/2 comparative study) | Effect size (95%CI): RR: 1.07 (0.95 to 1.21) | Study limitation: −1 | Inconsistency: None | Imprecision: None | Quality: ⚫⚫◯◯ Moderate |
| **Continence—6 months (≤ 1 pad versus > 1 pad) [Jorion, 1997; Westney, 2006; Bahler, 2011; Nguyen, 2017]** | Number of participants (studies): 513 (2 RCTs/2 comparative studies) | Effect size (95%CI): RR: 1.01 (0.95 to 1.07) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Continence—12 months (≤ 1 pad versus > 1 pad) [Jorion, 1997; Westney, 2006; Bahler, 2011]** | Number of participants (studies): 310 (1 RCT/2 comparative studies) | Effect size (95%CI): RR: 1.02 (0.93 to 1.13) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Low |
| **Time to achieve continence, months (0 pad versus ≥ 1 pad) [Altinova, 2009; Punnen, 2014]** | Number of participants (studies): 296 (1 RCT/1 comparative study) | Effect size (95%CI): MD: −1.29 (−3.13 to 0.54) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Very low |
| **Time to achieve continence, months (0 pad versus ≥ 1 pad) [Bahler, 2011]** | Number of participants (studies): 104 (1 RCT) | Effect size (95%CI): MD: −0.4 (95%CI Not reported), p = 0.61 | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Very low |
| **Time to achieve continence, months (≤ 1 pad versus > 1 pad) [Punnen, 2014]** | Number of participants (studies): 237 (1 comparative study) | Effect size (95%CI): MD: 0.5 (0.1 to 0.9) | Study limitation: −1 | Inconsistency: −1 | Imprecision: None | Quality: ⚫⚫◯◯ Very low |
| **Number of pads required—5 days [Cestari, 2015]** | Number of participants (studies): 60 (1 RCT) | Effect size (95%CI): MD: −0.2 (−0.9 to 0.5) | Study limitation: None | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Low |
| **Number of pads required—10 days [Cestari, 2015]** | Number of participants (studies): 60 (1 RCT) | Effect size (95%CI): MD: −0.5 (−1.2 to 0.2) | Study limitation: None | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Low |
| **Number of pads required—1 month [Cestari, 2015]** | Number of participants (studies): 60 (1 RCT) | Effect size (95%CI): MD: −0.7 (−1.2 to −0.2) | Study limitation: None | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Low |
| **Achieving immediate continence after catheter removal (0 pad versus ≤ 1 pad) [Altinova, 2009]** | Number of participants (studies): 59 (1 RCT) | Effect size (95%CI): RR: 1.31 (0.69 to 2.51) | Study limitation: None | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Low |
| **1-hour pad test—1 month [Kojima, 2014]** | Number of participants (studies): 57 (1 RCT) | Effect size (95%CI): MD: 21.55 (12.58 to 30.52) | Study limitation: −1 | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Very low |
| **1-hour pad test—3 months [Kojima, 2014]** | Number of participants (studies): 57 (1 RCT) | Effect size (95%CI): MD: 0.00 (−4.12 to 4.12) | Study limitation: −1 | Inconsistency: −1 | Imprecision: −1 | Quality: ⚫⚫◯◯ Very low |

(Continues)
| Outcome—Time point (definition) [references] | Number of participants (studies) | Effect size (95%CI) | Study limitation | Inconsistency | Imprecision | Quality |
|---------------------------------------------|---------------------------------|---------------------|------------------|---------------|-------------|---------|
| **1-hour pad test—6 months [Kojima, 2014]** | 57 (1 RCT)                      | MD: 0.41 (−0.79 to 1.91) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **IPSS—1 month [Kojima, 2014]**             | 57 (1 RCT)                      | MD: 4.75 (3.67 to 5.83) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **IPSS—3 months [Kojima, 2014]**            | 57 (1 RCT)                      | MD: 1.44 (0.14 to 2.74) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **IPSS—6 months [Kojima, 2014]**            | 57 (1 RCT)                      | MD: −0.94 (−1.90 to 0.02) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **ICIQ- SF—1 month [Kojima, 2014; Zanoni, 2020]** | 464 (1 RCT/1 comparative study) | MD: 2.77 (−1.54 to 7.08) | -1              | None          | None        | ⬤⬤⬤⬤ Moderate |
| **ICIQ- SF—3 months [Kojima, 2014]**        | 57 (1 RCT)                      | MD: 2.25 (1.26 to 3.24) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **ICIQ- SF—6 months [Kojima, 2014]**        | 57 (1 RCT)                      | MD: 0.5 (−0.63 to 1.63) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **EPIC urinary score—1 month [Kojima, 2014]** | 57 (1 RCT)                      | MD: 15.35 (11.37 to 19.33) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **EPIC urinary score—3 months [Kojima, 2014]** | 57 (1 RCT)                      | MD: 5.30 (1.21 to 9.39) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **EPIC urinary score—6 months [Kojima, 2014]** | 57 (1 RCT)                      | MD: 4 (−0.04 to 8.04) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |

**Postoperative complications**

| Disease                          | Number of participants (studies) | Effect size (95%CI) | Study limitation | Inconsistency | Imprecision | Quality |
|----------------------------------|---------------------------------|---------------------|------------------|---------------|-------------|---------|
| **Bladder neck contracture**     | [Jones, 2005; Bahler, 2016]     | RR: 2.98 (0.32 to 27.73) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |
| **Pelvic abscess**               | [Westney 2006; Bahler, 2016]    | RR: 0.38 (0.07 to 1.99) | -1              | None          | None        | ⬤⬤⬤⬤ Moderate |
| **Urethral Stricture**           | [Jones, 2005; Westney 2006; Bahler, 2016] | RR: 0.43 (0.24 to 0.75) | -1              | None          | None        | ⬤⬤⬤⬤ Low |
| **Urinary retention**            | [Jorion, 1997; Punnen, 2014]   | RR: 0.67 (0.07 to 6.14) | -1              | -1            | -1          | ⬤⬤⬤⬤ Very low |

**Length of hospital stay**

| Outcome                          | Number of participants (studies) | Effect size (95%CI) | Study limitation | Inconsistency | Imprecision | Quality |
|----------------------------------|---------------------------------|---------------------|------------------|---------------|-------------|---------|
| **Hospital stay length**         | [Cestari, 2015]                 | MD: 0.0; (p = NS)* | None             | -1            | -1          | ⬤⬤⬤⬤ Low |

**Length of operation**

| Outcome                          | Number of participants (studies) | Effect size (95%CI) | Study limitation | Inconsistency | Imprecision | Quality |
|----------------------------------|---------------------------------|---------------------|------------------|---------------|-------------|---------|
| **Length of operation**          | [Bahler, 2016; Kojima, 2014; Cestari, 2015; Zanoni, 2020] | MD: −6.13 (−9.18 to −3.07) | -1              | None          | None        | ⬤⬤⬤⬤ Moderate |

Note: CI, Confidence interval; RCT, Randomized controlled trials; RR, Relative Risk (value > 1 favors sling); MD, Mean difference (negative values favors sling); IPSS, International Prostate Symptom Score; ICIQ-SF, International Consultation on Incontinence score short form; EPIC, Expanded Prostate Cancer Index Composite.

*Both groups presented the same mean and SD and therefore MD and 95%CI were zero.
reduces the time taken to achieve continence with ≤1 pad/day definition but not with zero pad/day definition.

Our meta-analysis also demonstrated that intraoperative sling may reduce the incidence of postoperative complications such as urethral stricture and urinary retention, however, no explanation as to why this is the case was provided in the included studies. Sling procedure increased the operative time but did not affect the length of hospital stay.

4.1 | Strengths and limitations of the study

The strengths of this systematic review include strict adherence to the Cochrane Collaboration guideline and PRISMA guidelines, registration of the protocol on PROSPERO, utilization of a highly sensitive search strategy with no language and date restriction, inclusion of RCTs, strict assessment of quality with the Cochrane risk of bias tool and Newcastle-Ottawa Scale and use of the GRADE approach for evidence appraisal.

This review has some limitations. First, intraoperative sling procedure is a relatively new technique in the literature, and thus, only five RCTs were identified and included in our analysis. Moreover, the inclusion of nonrandomized comparative studies and difficulty in standardizing the tension of the sling, surgical technique, and sling material may have influenced the results. This systematic review also does not include data from ongoing studies, studies published as abstract only and unpublished RCTs. Furthermore, variability in continence measurements resulted in very-low-quality evidence of data due to inability to perform meta-analyses for many continence outcomes.

4.2 | Comparison with other studies and future directions

To our knowledge, this is the first systematic review and meta-analysis that evaluates the effectiveness of intraoperative sling procedures compared to having no sling procedures on postprostatectomy continence outcomes. Our review demonstrates the importance of standardizing the definition of continence for utilization in future studies. Although defining continence via pad number is a common clinical practice, it is not a reliable measure of urine leakage as it is largely affected by pad size and type as well as the variability of individual patient’s perception of when to change the pads. Thus, pad weight measurement via 24-hour pad test is a more objective assessment of urinary incontinence for use in future studies. Additionally, questionnaires are objective assessment tools that also allow the evaluation of patient’s postoperative quality of life, and thus, provide a better assessment of sling effectiveness.

Furthermore, our review demonstrates that current studies in the field of intraoperative sling technique have very-low-quality to moderate-quality, identifying the need for future studies with high-quality evidence.

Our review also suggests that future studies assessing the effectiveness of intraoperative sling must consider the type of sling material used. The sling materials used in all studies included in our review are biological absorbable graft materials, and as they are known to degrade very quickly, this may be one reason for poor outcome. Our review demonstrates that there are no significant difference in continent patients between the sling and no-sling group beyond 6 months postoperatively. This may be influenced by the fact that biological sling materials are absorbed after 6 months.

5 | CONCLUSION

Overall, our study demonstrates that intraoperative sling procedures do not decrease long-term urinary incontinence rate, however, may have potential to promote early return of continence. Currently, our evidence is limited by the lack of high-quality studies and variability in definitions, and as thus our study details how future clinical research in this field can be improved in order to verify the effect of intraoperative slings more effectively.

CONFLICTS OF INTEREST

None.

ORCID

Eunice Lim https://orcid.org/0000-0002-4736-6355

REFERENCES

1. Globocan. Prostate cancer: World Health Organization. 2018. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—Update 2013. Eur Urol. 2014;65(1):124–37. https://doi.org/10.1016/j.eururo.2013.09.046
3. Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):405–17.
4. Singla N, Singla AK. Post-prostatectomy incontinence: Etiology, evaluation, and management. Turk J Urol. 2014;40(1):1–8.
5. Kojima Y, Takahashi N, Haga N, Nomiyama M, Yanagida T, Ishibashi K, et al. Urinary incontinence after robot-assisted radical prostatectomy: Pathophysiology and intraoperative techniques to improve surgical outcome. Int J Urol. 2013;20(11):1052–63.
6. Lim SK, Kim KH, Shin TY, Han WK, Chung BH, Hong SJ, et al. Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retroperitoneal and perineal approaches. BJU Int. 2014;114(2):236–44.
7. Reeves F, Preece P, Kapoor J, Everaerts W, Murphy DG, Corcoran NM, et al. Preservation of the neurovascular bundles is associated with improved time to continence after radical prostatectomy but not long-term continence rates: Results of a systematic review and meta-analysis. Eur Urol. 2014;68(4):692–704.
8. Ma X, Tang K, Yang C, Wu G, Xu N, Wang M, et al. Bladder neck preservation improves time to continence after radical

LIM ET AL.
prostatectomy: a systematic review and meta-analysis. Oncotarget. 2016;7(41):67463–75.

9. Rocco B, Cozzi G, Spinelli MG, Coelhio RF, Patel VR, Tewari A, et al. Posterior musculofascial reconstruction after radical prostatectomy: A systematic review of the literature. Eur Urol. 2012;62(5):779–90.

10. Westney OL, Scott S, Wood C, Eddings T, Johnson MM, Taylor JM, et al. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU Int. 2006;98(2):308–13.

11. Bauer RM, Bastian PJ, Gozzi C, Stief CG. Postprostatectomy incontinence: All about diagnosis and management. Eur Urol. 2008;55(2):322–33.

12. Higgins JGS. Cochrane handbook for systematic reviews of interventions 2011. Available from: www.cochrane-handbook.org

13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535

14. Wells GA, Shea B, O’Connell DA, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.

15. Higgins JP, Green S. The Cochrane Collaboration. Section 13.5.2.3. Tools for assessing methodological quality or risk of bias in non-randomized studies; 2011.

16. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.

17. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis Version 3; 2013.

18. Bahler CD, Sundaram CP, Kella N, Lucas SM, Boger MA, Gardner TA, et al. A parallel randomized clinical trial examining the return of urinary continence after robot-assisted radical prostatectomy with or without a small intestinal submucosa bladder neck sling. J Urol. 2016;196(1):179–84.

19. Cestari A, Ferrari M, Ghezzi M, Sangalli M, Zanoni M, Fabbri F, et al. Retropubic intracorporeal placement of a suburethral autologous sling during robot-assisted radical prostatectomy to improve early urinary continence recovery: Preliminary data. J Endourol. 2015;29(12):1379–85.

20. Altinova S, Demirci DA, Ozdemir AT, Akbulut Z, Atmaca AF, Caglayan A, et al. Incorporation of anterior rectus fascial sling into radical retropubic prostatectomy improves postoperative continence. Urol Int. 2009;83(1):19–21.

21. Kojima Y, Hamakawa T, Kubota Y, Ogawa S, Haga N, Tozawa K, et al. Bladder neck sling suspension during robot-assisted radical prostatectomy to improve early return of urinary continence: a comparative analysis. Urology. 2014;83(3):632–9.

22. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, et al. A randomized study of intraoperative autologous retropubic urethral sling on urinary control after robotic assisted radical prostatectomy. J Urol. 2017;197(2):369–75.

23. Jones JS, Vasavada SP, Abdelmalak JB, Liou L, Ahmed ES, Zippe CD, et al. Sling may hasten return of continence after radical prostatectomy. Urology. 2005;65(6):1163–7.

24. Jorion JL. Rectus fascial sling suspension of the vesicourethral anastomosis after radical prostatectomy. J Urol. 1997;157(3):926–8.

25. Punnen S, Clint Cary K, Glass A, Cowan J, Carroll P. Autologous retro-pubic urethral sling: A novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. Journal of Robotic Surgery. 2014;8(2):99–104.

26. Zanoni ML, Grizzi F, Maffei D, Vota P, Frego N, Toia G, et al. Retrotrigonal muscular layer sling associated with total anatomical reconstruction in robot-assisted radical prostatectomy and early continence. World J Urol. 2020. https://doi.org/10.1007/s00345-020-03500-9

27. Syan RN. Post-prostatectomy incontinence initial evaluation; 2016.

28. Tsui JF, Shah MB, Weinberger JM, Ghanaat M, Weiss JP, Purohit RS, et al. Pad count is a poor measure of the severity of urinary incontinence. J Urol. 2013;190(5):1787–90.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Lim E, Leslie S, Thanigasalam R, Steffens D. To sling or not to sling? Impact of intraoperative sling procedures during radical prostatectomy on postoperative continence outcomes: A systematic review and meta-analysis. BJUI Compass. 2021;2:226–237. https://doi.org/10.1002/bco2.67